Expert co-authors examine the opportunity to evolve current HTA approaches for the evaluation of precision oncology therapeutics by extending the window for evidence generation and decision-making to the full lifecycle of a technology.
Despite the growing body of evidence, our understanding of barriers to healthcare encountered by individuals with Autism Spectrum Disorder (ASD) remains limited, particularly beyond childhood and outside higher resource countries (HRCs).
Research Canada, in partnership with Shift Health, recently convened an Expert Advisory Panel to conduct an independent study examining the role of the biopharmaceutical industry within Canada’s health research and innovation ecosystem.
Our recently published Health Intelligence report, “Maximizing the Value of Cannabis-Based Pharmaceuticals,” examines how innovators can maximize the value of cannabis-based pharmaceuticals for patients, prescribers and payers.
Building on our recently published Health Intelligence report on inclusion, diversity, equity and accessibility (IDEA), we convened an exceptional panel of leaders for a webinar to discuss embedding IDEA in research-intensive organizations.
As we explore in our Longwoods publication, clinical research can better position community hospitals to test and adopt cutting-edge products, and increase the cost-effectiveness and quality of care.
For research-intensive organizations, COVID-19 and our collective awakening to the insidious realities of racism have exposed the limitations of accepted approaches to inclusion, diversity, equity and accessibility.
We convened a virtual roundtable in collaboration with Life Sciences Ontario (LSO), featuring a diverse panel of leaders, on what COVID-19 is teaching us and how we can prepare our health research and innovation ecosystem for a resilient, productive and impactful future.
We argue that the pandemic represents an inflection point for the health research and innovation system. There has never been greater recognition that “science is the solution”. There has never been a more fertile moment to reinvigorate investment in health research and innovation and create the best system possible.